BMRN
Biomarin Pharmaceutical Inc. - Registered Shares

5,216
Loading...
Loading...
News
all
press releases
Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Zacks·3d ago
News Placeholder
More News
News Placeholder
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·8d ago
News Placeholder
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·10d ago
News Placeholder
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·14d ago
News Placeholder
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·24d ago
News Placeholder
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·29d ago
News Placeholder
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·1mo ago
News Placeholder
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
Zacks·1mo ago
News Placeholder
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago

Latest BMRN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.